Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Is Bouncing Back Today

By Keith Speights – Aug 26, 2020 at 11:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Some investors appear to think the sell-off earlier this week went too far.

What happened

Shares of Sorrento Therapeutics (SRNE 6.13%) were up 4.7% as of 10:33 a.m. EDT on Wednesday after rising as much as 14.9% earlier in the day. Why did the stock bounce back after plunging earlier this week? Sorrento didn't report any news that would provide a catalyst. Instead, it appears that some investors viewed the sell-off as overdone.

So what

The kind of volatility seen with Sorrento isn't unusual for a clinical-stage biotech stock. That's especially true for biotechs developing experimental COVID-19 therapies and vaccines, an area that's moving at a blazingly fast pace.

$1 bill folded into an arrow pointing up

Image source: Getty Images.

Sorrento's decline earlier this week stemmed from a couple of stories in the fight against COVID-19. The U.S. Food and Drug Administration (FDA) gave emergency use authorization (EUA) to convalescent plasma in treating COVID-19 on Sunday. The Financial Times also reported on Sunday that the COVID-19 vaccine candidate being developed by AstraZeneca and the University of Oxford could be fast-tracked for EUA by the Trump administration.

The EUA for convalescent plasma could have a greater impact on Sorrento. It's possible that the antibody therapies the biotech is developing could have a harder time gaining market share (assuming approval) if convalescent plasma proves to be effective in treating COVID-19. However, some investors appeared to realize today that all of this is only conjecture.

Now what

Sorrento doesn't have any coronavirus-related products on the market yet. That could change in the not-too-distant future, though. The company hopes to soon receive EUA for its COVI-TRACK antibody test. It also expects to file for an EUA for its COVI-TRACE diagnostic test. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.65 (6.13%) $0.10
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$57.00 (2.61%) $1.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.